Diabetes is a serious, life-threatening disease caused by improper absorption and metabolism of glucose. Increased glucose levels can lead to an accumulation of toxic sugar degradation products, such as methylglyoxal (MG), in the bloodstream. MG is a reactive molecule which can modify and inactivate blood proteins which in turn leads to hypertension, neuropathy, and heart disease. Consequently, MG has been shown to be an excellent biomarker for a number of diabetes-related complications. Unfortunately, all current methods to directly measure MG levels in blood are very expensive, time-consuming and laborious. To fully realize the diagnostic potential of MG, rapid analytical methods are needed for the routine determination of MG in biomedical samples such as blood. Our proposed Phase I research will create a unique test to measure MG levels in blood samples such as plasma and serum. This unique test will permit researchers to conveniently study the accumulation of reactive MG in blood before damage to proteins and vasculature has occurred. Our novel assay will use a recombinant bacterial oxidoreductase enzyme (MG-R) capable of specifically and rapidly converting MG into a detectable colorimetric signal in a 96 well plate assay format. To boost sensitivity, we will link our enzymatic detection reaction to an NADP+/NADPH visible colorimetric amplification loop to increase assay sensitivity more than 100-fold. The assay will be optimized and validated using rat and mouse plasma and serum spiked with known amounts of MG. After validation, we will commercially launch a rapid test kit to directly detect MG in preclinical and other biomedical samples.

Public Health Relevance

Diabetes is a major health threat in the US;this life-threatening disease is rapidly spreading throughout our country (23 million Americans currently affected). Recently, scientists have discovered that a sugar metabolite called methylglyoxal plays a central role in the progression of diabetes - unfortunately there are no methods currently available for routine analysis of methylglyoxal. Our research will create a unique method to rapidly measure methylglyoxal levels in normal and diabetic blood samples;our new analytical method will provide researchers with a critical new diagnostic tool to more-effectively combat diabetes and associated cardiovascular disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43DK095653-01A1
Application #
8455478
Study Section
Special Emphasis Panel (ZRG1-EMNR-S (11))
Program Officer
Arreaza-Rubin, Guillermo
Project Start
2013-01-22
Project End
2014-12-31
Budget Start
2013-01-22
Budget End
2014-12-31
Support Year
1
Fiscal Year
2013
Total Cost
$161,703
Indirect Cost
Name
Bioo Scientific Corporation
Department
Type
DUNS #
611930244
City
Austin
State
TX
Country
United States
Zip Code
78744